In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy

Journal of Pharmacological and Toxicological Methods
Behzad ForoutanDiana Anderson

Abstract

Resistance to an anthracycline-based regimen, such as CHOP, constitutes a problem for curing non-Hodgkin's lymphoma (NHL) patients. Chemoresistance in the clinic manifests itself as a lack of response to treatment or regrowth of a tumour after an initial response. In this study, lymphocytes from NHL patients were treated with hydrogen peroxide (H(2)O(2)), a free radical generating model agent, and ethyl methanesulfonate (EMS), a model alkylating agent, to induce DNA damage which was evaluated by SCGE. This study assessed whether or not there were any differences in the patterns of damage and repair between cells from patients with p53 mutant protein abnormalities, i.e. over-expression (p53(+)) not responding to the CHOP regimen and patients responding to the CHOP regimen without p53 protein abnormalities (p53(-)) by comparison with control individuals (wild-type). An NHL cell line model [Raji TK(+) (mex(+)) and TK(-) (mex(-))] with p53 over-expression was also investigated. Results showed that frozen/thawed samples from healthy people were not suitable for use in repair studies, whilst fresh samples or samples incubated for 20 h at room temperature could be used. Tumour cells were more sensitive to damage than control cells. Af...Continue Reading

References

Feb 1, 1988·Trends in Pharmacological Sciences·M M Gottesman, I Pastan
Mar 1, 1988·Experimental Cell Research·N P SinghE L Schneider
Aug 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·P Karran
Oct 1, 1993·Environmental Health Perspectives·R J AlbertiniJ P O'Neill
Oct 28, 1993·The New England Journal of Medicine·C C Harris, M Hollstein
Jan 1, 1996·Environmental and Molecular Mutagenesis·S Pfuhler, H U Wolf
May 1, 1996·Genes & Development·L J Ko, C Prives
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Lehnert
Feb 1, 1996·Current Opinion in Genetics & Development·S Bates, K H Vousden
Jan 1, 1997·Current Opinion in Oncology·W S el-Deiry
Jun 25, 1998·Leukemia & Lymphoma·S NavaratnamJ B Johnston
Mar 29, 2000·Environmental and Molecular Mutagenesis·R R TiceY F Sasaki
Sep 7, 2000·Current Opinion in Oncology·B TanL Ratner

❮ Previous
Next ❯

Citations

Feb 2, 2008·The Journal of Pharmacy and Pharmacology·Song-Qiang XieBian-Sheng Ji
Mar 5, 2011·Molecular Carcinogenesis·Claudia M MonroyRanda El-Zein
Jul 28, 2006·Journal of Pharmacological and Toxicological Methods·Behzad ForoutanDiana Anderson
Dec 12, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Xiang WangQing Mao
Aug 30, 2013·Experimental Biology and Medicine·Steve A Maxwell, Seyed Mousavi-Fard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.